KaloBios Comments on Recent Scientific Publication Reporting Significantly Higher Risk of Death Associated With Chagas Infection
May 25, 2017 10:18 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios to Host Company Overview Webinar on May 10
May 03, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
Benznidazole on Track in Progress to IND and NDA Submissions
April 06, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
Investigational new drug (IND) application on track to be submitted in May 2017Manufacturing preparations in line to produce tablets, clinical batches producedCompany anticipates filing new drug...
KaloBios to Participate in Inaugural U.S. Chagas Conference
March 30, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Receives M&A Advisor 2017 Turnaround Award
March 27, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Receives $5.5M in New Financing From Existing Investors
March 23, 2017 16:10 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios to Present at 29th Annual ROTH Conference
March 09, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios to Present at Disruptive Growth & Healthcare Conference
February 13, 2017 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Announces Positive Guidance from FDA for Benznidazole
January 05, 2017 11:20 ET
|
KaloBios Pharmaceuticals Inc.
Minutes received from recent FDA meeting on benznidazole 505(b)(2) regulatory pathway using existing safety and efficacy data is acceptable Benznidazole eligible for neglected tropical...
KaloBios CEO to Participate at FDA/CMS Summit
December 13, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...